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HCCInteraction between HBV and host genome integrations in hepatocellular carcinoma (HCC) development is a
complex process and the mechanism is still unclear. Here we described in details the quality controls and data
mining of aCGH and transcriptome sequencing data on 50 HCC samples from the Chinese patients, published
by Dong et al. (2015) (GEO#: GSE65486). In additional to the HBV-MLL4 integration discovered, we also investi-
gated the genetic aberrations of HBV and host genes aswell as their genetic interactions.We reported human ge-
nome copy number changes and frequent transcriptome variations (e.g. TP53, CTNNB1mutation, especiallyMLL
familymutations) in this cohort of the patients. For HBV genotype C, we identiﬁed a novel linkage disequilibrium
region covering HBV replication regulatory elements, including basal core promoter, DR1, epsilon and poly-A re-
gions, which is associatedwith HBV core antigen over-expression and almost exclusive to HBV-MLL4 integration.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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aCGH proﬁling data have been deposited to the GEO database and
can be found here: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE65484.
RNASeq proﬁling data have been deposited to the GEO database and
can be found here: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE65485.
Superseries accession GSE65486 links the CGH and RNA-Seq studies
together: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE654
86.2. Experimental design, materials and methods
2.1. RNASeq data quality control
Clinical characteristics of HCC patients could be obtained in Table 1
of PLOS One paper [1]. Patients and their tumor specimen collection,
processing and proﬁling steps were also described in the Materials
and methods section in the paper [1]. However, the quality control
steps for RNASeq data were not given in details previously. Hence, we
showed the RNASeq data QC in Supplementary Table 1. Raw fastq data
were mapped by ArrayStudio OSA (http://omicsoft.com/osa) [2]. Total
mapped reads greater than 60 M were considered to pass QC. 5′ to 3′
ratios were used to assess the RNA sample quality.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Gene copy number (GCN) change was proﬁled by Agilent 244K
array. ArrayCGH log2 ratios greater than 0.2 and less than−0.3 were
considered as the GCN gain and loss, respectively; and ArrayCGH log2
ratios greater than 0.8 and less than−0.8were considered as ampliﬁca-
tion and deletion, respectively. Chromosome segments of themost GCN
gain or loss frequency were provided in Supplementary Table 2. We
then looked into genes within those segments, and found genes
encoded for cell adhesion molecules, including NCAM2, CDH8, CDH13
and CADM2, were GCN loss with frequency of 22%, 66%, 70% and 10%,
respectively. Similarly, tumor suppressor genes, such as RB1, MYH2,
CDKN2A, PTEN and APC were also lost with high frequency of 66%, 62%,
38%, 28% and 12%, respectively. In addition to the GCN loss, gene ampli-
ﬁcations were also observed, which include c-MYC, TPPP, CCND1, PIM1
and c-MET with frequency of 26%, 18%, 2%, 2% and 4%, respectively.
Interestingly, CCND1/FGF19, PIM1 and c-MET genes showed focal ampli-
ﬁcations. Gene deletion was observed for UGT2B17, CDKN2A, CDH8 and
RB1with frequency of 44%, 8%, 6% and 2%, respectively.
2.3. Human transcriptome variation in HCC
Analysis of the RNASeq data on those 50 HCC samples revealed that
the most frequently recurred cancer mutation genes with hotspot are
TP53 (44%, 22/50) and CTNNB1 (18%, 9/50). Two mutation hotspots of
TP53, R249S and 142Ins_fs*7 observed at frequency of 27% (6/22) and
9% (2/22) in the HCC patients, respectively. Besides the previously
reported non-hotspot gene mutations, such as mutations of AXIN1,
MLL3 and ARID1A [3,4], novel gene mutations were also identiﬁed in the
HCC samples, which included epigenetic related gene, virus infection/
transcription related genes and others. Among the epigenetic and nucle-
oprotein gene, mutations occurred inMLL2, MLL3, NPIP, LOC100132247
(NPIP like), BPTF and NCPR2 with frequency of 14%, 14%, 12%, 22%, 10%
and 14% in HCC, respectively. For the virus infection relevant gene, muta-
tionswere found inHAVCR1, SON andCPDwith frequency of 18%, 12% and
10%, respectively. Furthermore, hotspot mutations were also identiﬁed
for genes ofMLL3, LOC100132247, AHDC1, CPD, ARAP1 and AGAP6. All of
these transcriptome mutations identiﬁed in HCC were summarized in
Supplementary Table 3.
2.4. HBV genotype C variations and their linkage disequilibrium in
HCC patients
In a previous paper, we reported that HBV transcripts were detected
in 88% (44/50) of theHCC samples, of which 77% (34/44) exhibitedHBV
genotype C, and 23% (10/44) were HBV genotype B. Expression of HBV
transcription showed a segmented pattern with four peaks identiﬁed in
the HBx-pre core region, prior to HBx, pre-S2, and S regions. In those
HBV expressed regions, we further identiﬁed HBV mutations which oc-
curred frequently in the 33HBV genotype C positive patients.Moreover,
high frequency of mutations identiﬁed at the important HBV regulatory
regions of core promoter (nucleotides 1751–1769), DR1 (nucleotides
1824–1835), epsilon (nucleotides 1847–1907) and poly A signal (nucle-
otides 1916–1921). They included 14.8% T1753C, 54.2% A1762T, 33.3%
G1764A, 52.2% C1827A, 42.9% A1846C/T, 21.3% G1896A, 21.4% C1913A
and 21.4% G1915C. Among those HBV mutations, A1753, A1762 and
G1764 are located within HBV ORF X. The others, A1846, G1896,
C1913 and G1915 are located within pre-core/core ORF, which all
were relevant to HCC carcinogenesis [5].We categorized HBV variations
and high frequent mutant human genes in Fig. 1a.
To further understand HCC patients infected with the mutated HBV,
HBV linkage disequilibrium was investigated in the 34 HCC patients
who had HBV genotype C. A speciﬁc linkage disequilibrium (LD) region
in HBV was identiﬁed in those carrying frequent HBV mutations (black
box region in Fig. 1b). Interestingly, we observed 15-fold increases in
the transcription of pre-core/core ORF in HCC patient harboring HBVmutants in LD region compared to those harboring the wild type HBV
(Fig. 1b).
2.5. Exclusivity between HBV-MLL4 gene integration and HBV regulatory
region mutations
To further understand potential interaction between HBV infection
and human gene variations in HCC, we analyzed the exclusivity be-
tween HBV mutation and the host genes with high frequent variations
based on known functionality, such as TP53, CTNNB1, PTEN and MET.
As shown in Fig. 1a, epigenetic gene mutations occurred more frequent
(65%) in the HCC patients infected with HBV genotype C compared to
that (33%) in HCC patients without HBV infection. Interestingly, HBV
mutants were exclusive to MLL4 fusion, but correlated with MLL2 and
MLL3 mutation (proportion test, p b 0.05). Speciﬁcally, only 14% (1/7)
of HBxA1762T/G1764Amutantswere found in theMLL4 fusion positive
HCC compared to 50% (13/26) of that identiﬁed in MLL4 wild-type HCC
(Fisher exact test, p = 0.195, odds ratio = 0.17). Meanwhile, frequent
mutation ofMLL2,MLL3 and ARID1Awas observed in LD regionmutants.
3. Discussions
HBV mutations play an important role in HBV infection, and subse-
quently HCC development [5]. HBV genome is evolving during chronic
infection, balancing between virus replication and cellular stress
induced by virus replication. As the result, mutations accumulated in
HBV genome, either contributing to immune escape or enhancing
virus transcription/replication. Our results validated most reported
high risk HBV mutations [5–7], including HBx mutation, dual mutation
of A1762T/G1764A, and point mutations of G1896A, C1653T, T1753V,
and HBx5 (C1386G/A). Among them, A1762T/G1764A and G1896A
were reported to enhance virus replication, which might contribute to
severe hepatocyte damage and cirrhosis. HBV replication regulatory
mutations are one of the high risk factors for HCC, supported by pro-
spective studies [5].We identiﬁed speciﬁc linkage disequilibriumwithin
this region, which contains basal core promoter, pre-core and DR1
sequences. It was the ﬁrst report on the speciﬁc linkage disequilibrium
in HCC to our best knowledge. The mutations induced signiﬁcant in-
crease of HBV core antigen expression. Further analysis of clinical out-
comes of the patients showed that the HBV mutations in this linkage
disequilibrium associated with worse progression free survival in this
cohort of HCC patients although the p-value is not signiﬁcant (data
not show).
Compared with other solid malignancies, development of targeted
therapies against HCC has been lagging mainly due to lack of identiﬁed
oncogenic drivers, which is complicated by chronic viral infection and
inﬂammation. Therefore, understanding of interactions between viral
infection and human genetic aberrations may facilitate identiﬁcation
of novel driver mutations for design new personalized strategy to
treat HCC. The observed association between MLL4 fusions and muta-
tions inMLL2/3 and ARID1A genes points out a new direction for further
investigation of the sequence of the genetic aberrations and their path-
ological impacts on initiation, development and maintenance of HCC.
The TP53 and CTNNB1 hotspot mutations and functions in HCC
development were well studies previously [8]. Here we found new
hotspots mutation of TP53 142Ins_fs*7, which is rarely reported. Thera-
peutics targeting mutant TP53 and CTNNB1 are now in early clinical
development [9,10]. It is intriguing to test the efﬁcacy of these drugs
in HCC patients carrying TP53 or CTNNB1mutations.
In summary, by aCGH and RNASeq proﬁling, we found both human
and HBV genome and transcriptome variations in Chinese HCC. For
HBV, a novel linkage disequilibrium region covering HBV replication
regulatory elements was identiﬁed, including basal core promoter,
DR1, epsilon and polyA regions, which was associated with HBV core
antigen over-expression. For the human genetic lesions, 46% (N = 50)
of HCC patients harbored MLL family mutations, including MLL2
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Fig. 1. (a).Overlapping view of interactions between HCC genetics lesions and HBV variants.MLL4 fusion (blue ﬁll), gene mutations (red ﬁll), andMET ampliﬁcation (orange ﬁll) were
aligned to HBV genotypes and DR1mutants (blank: wild type, red: mutant, gray, no reads covered). (b) Linkage disequilibrium analyses of all HBV mutations detected in current study
revealed DR1 region is functional important for HCC.
3H. Dong et al. / Genomics Data 6 (2015) 1–3mutations, MLL3mutations and HBV-MLL4 fusion. Moreover, frequent
epigenetic gene variations in HCC patients, which were enriched in
HBV genotype C infection subgroup suggested thatMLL4 and epigenetic
mutations could be potential targets for treatment of HCC patients who
are HBV type C positive.
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.gdata.2015.07.018.
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